A novel synthesis method of 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranyl)-2(1H)-pyrimidinone

Through a new three-step reaction method, the synthesis efficiency of the nucleoside analog 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinfuranyl)-2(1H)-pyrimidinone was improved. The problems of medium and low yields and high costs in the prior art have been solved, and more efficient production has been achieved.

CN118373865BActive Publication Date: 2024-11-08SUZHOU NOVIKON BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410824085.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-08
Estimated Expiration
2044-06-25

AI Technical Summary

Technical Problem

The synthesis route of existing nucleoside analogs requires 4 steps of reaction, with low overall yield and high cost, which is not conducive to post-amplification production.

Method used

Using a new synthesis method of 3-step reaction, the amine on cytosine is protected by HMDS, and ammonium sulfate catalyzed the Sn2 substitution reaction, followed by acetic anhydride and sodium hydroxide treatment to obtain 4-acetylamino-1-(2-deoxy-2-fluorine -beta-D-Arabinofuranyl)-2(1H)-pyrimidinone.

Benefits of technology

The reaction steps are shortened, the total yield is increased from 55.0% to 65.3%, and the production costs are reduced, making it suitable for later-scale production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118373865B_ABST
    Figure CN118373865B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of nucleoside pharmaceutical intermediates, and specifically discloses a novel synthesis method of 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone, comprising the following steps: (1) protecting the amine group on cytosine with trimethylsilyl by HMDS to obtain intermediate 1; reacting intermediate 1 with compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate) under the catalytic action of ammonium sulfate, and then removing the protection of trimethylsilyl by hydrolysis to obtain compound 2; (2) acetylating the amino group of compound 2 by acetic anhydride to obtain compound 3; and (3) removing two benzoyl groups by hydrolysis reaction with sodium hydroxide to finally obtain compound 4, i.e., 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of nucleoside pharmaceutical intermediates and specifically discloses a new synthesis method of 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranyl)-2(1H)-pyrimidinone. Background Art

[0002] Nucleoside analogs are good substrates for cellular kinases and resistant to other host enzymes such as phosphorylases and deaminases, which are potentially important for the development of therapeutic agents.

[0003] The search for nucleoside analogs as selective inhibitors of polymerases and other enzymes for the control of viral diseases and cancer has been a hot topic of research, including some modifications of sugar moieties and heterocycles to circumvent the inactivation caused by enzymatic degradation of some of these nucleosides. The important discovery in this field so far is that the replacement of the hydroxyl group of the sugar moiety of nucleosides with fluorine produces nucleoside analogs that have been found to have interesting biological activities. For example, clofarabine, synthesized in the applicant's laboratory, is currently undergoing human clinical trials and has strong anti-leukemia activity.

[0004] The prior art discloses a cytidine analog compound D1, and its synthesis route is as follows: Figure 1 As shown:

[0005] The synthesis method of step A can be found in the literature (Current Patent Assignee: NANYANGTECHNOLOGICAL UNIVERSITY-US2011 / 245458, 2011, A1);

[0006] The synthesis method of BC in the above step can be found in the literature (Current Patent Assignee: SHANGHAIYAOTAN PHARMACEUTICAL RES DEVELOPMENT-CN115960147,2023,A);

[0007] The synthesis method of the above step D can be specifically found in the literature (Current Patent Assignee: SANOFIAVENTIS DEUTSCHLAND-US6420546, 2002, B1).

[0008] The above synthesis route requires 4 steps of reaction with a total yield of 55.0%, which is costly and not conducive to subsequent scale-up production. Summary of the invention

[0009] In view of the above problems, the present invention discloses a new synthesis method of 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranyl)-2(1H)-pyrimidinone.

[0010] The purpose of the present invention is achieved through the following technical solutions.

[0011] A novel method for synthesizing 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone, wherein the synthetic route is as follows: Figure 2 , the reaction mechanism is as follows Figure 3 As shown, the following steps are included:

[0012] (1) The amine on cytosine is protected with trimethylsilane by HMDS (hexamethyldisilazane) to obtain intermediate 1; under the catalytic action of ammonium sulfate, the amide nitrogen of intermediate 1 attacks the carbon at the 1' position of compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate), the bromine anion leaves, and a Sn2 substitution reaction occurs. After hydrolysis, the trimethylsilane protection is removed to obtain compound 2;

[0013] (2) Acetylation of the amino group of compound 2 with acetic anhydride to obtain compound 3;

[0014] (3) Hydrolysis of the two benzoic acid esters was achieved by sodium hydroxide to finally obtain compound 4, namely 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone;

[0015] Furthermore, in the above novel synthesis method, the step (1) comprises the following steps:

[0016] 1) Add 46.44 g of HMDS (hexamethyldisilazane) into the reactor R1 under nitrogen protection;

[0017] 2) Add 12.0 g of cytosine into the reactor R1 under nitrogen protection;

[0018] 3) Adjust the temperature of the reactor to 135°C and continue stirring the reaction for 3 hours;

[0019] 4) The reaction is complete during HPLC control;

[0020] 5) The reaction liquid in R1 is evaporated to dryness under reduced pressure using an oil pump to obtain intermediate 1;

[0021] 6) Add 226.4 g CHCl3, 0.12 g ammonium sulfate and 30.0 g compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate) to R1;

[0022] 7) Adjust the temperature to 80°C;

[0023] 8) Continue stirring for 15 hours;

[0024] 9)HPLC central control;

[0025] 10) Adjust the temperature of reactor R1 to 20-25°C;

[0026] 11) Add 72 g of water to wash the organic phase;

[0027] 12) Add anhydrous sodium sulfate, dry, and filter;

[0028] 13) Concentrate under reduced pressure to obtain compound 2.

[0029] Furthermore, in the above novel synthesis method, the step (2) comprises the following steps:

[0030] 1) Under nitrogen protection, cool 100 mL of dry pyridine solution containing 27 g of compound 2 to 0-5 °C;

[0031] 2) Add 7.3 g of acetic anhydride dropwise;

[0032] 3) Stir overnight at room temperature;

[0033] 4) HPLC central control;

[0034] 5) Add 5 mL of methanol to quench the reaction;

[0035] 6) Concentration under reduced pressure;

[0036] 7) The crude product was purified by column chromatography to obtain compound 3.

[0037] Furthermore, in the above novel synthesis method, the step (3) comprises the following steps:

[0038] 1) Under ice bath, dissolve 25 g of compound 3 in 50 mL of 1,4-dioxane;

[0039] 2) At 0-5°C, slowly add 50.5 mL of 1 mol / L NaOH aqueous solution;

[0040] 3) HPLC detection reaction;

[0041] 4) After the reaction is completed, add a methanol solution containing 1 mol / L acetic acid at 0-5°C until the pH is 6-7;

[0042] 5) Concentrate the organic phase under reduced pressure;

[0043] 6) Purify by column chromatography to obtain compound 4.

[0044] Compared with the existing technology, the present invention has the following advantages and beneficial effects:

[0045] As an important intermediate for cytidine analogs produced by replacing the hydroxyl group of the sugar part of nucleoside with fluorine, we developed a synthetic route to reduce the cost. The original process required 4 steps of reaction, and the total yield was: 55.0%

[0046] However, the present application only requires three steps of reaction, and the total yield is 65.3%, which shortens the reaction steps and improves the yield, has obvious advantages, and is conducive to later scale-up production. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 . The synthetic route of the cytidine analog compound D1 in the background technology of the present invention;

[0048] Figure 2 . The synthetic route of 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone of the present invention;

[0049] Figure 3 . The synthesis mechanism of 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone of the present invention;

[0050] Figure 4 . The structural diagram of the product 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone obtained in the present invention;

[0051] Figure 5 . The H NMR spectrum of the pharmaceutical intermediate 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone prepared by the present invention;

[0052] Figure 6 .The HPLC purity spectrum of the pharmaceutical intermediate 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone prepared by the present invention, the HPLC purity is greater than 97%. DETAILED DESCRIPTION

[0053] A novel method for synthesizing 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone, wherein the synthetic route is as follows: Figure 2 As shown, the following steps are included:

[0054] (1) The amine on cytosine is protected with trimethylsilane by HMDS (hexamethyldisilazane) to obtain intermediate 1; under the catalytic action of ammonium sulfate, the amide nitrogen of intermediate 1 attacks the carbon at the 1' position of compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate), the bromine anion leaves, and a Sn2 substitution reaction occurs. After hydrolysis, the trimethylsilane protection is removed to obtain compound 2;

[0055] (2) Acetylation of the amino group of compound 2 with acetic anhydride to obtain compound 3;

[0056] (3) The two benzoyl groups are removed by hydrolysis with sodium hydroxide to obtain compound 4, namely 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone.

[0057] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below through the accompanying drawings and embodiments. However, it should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the scope of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concept of the present invention.

[0058] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below in conjunction with the embodiments.

[0059] The following are the main reagents used in the examples of the present invention.

[0060] HMDS (hexamethyldisilazane) is a product produced by Anaiji with batch number YJRBRREF;

[0061] Compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate) is a product with batch number NVC0028-16 produced by Suzhou Novicon Biotechnology Co., Ltd.; cytosine is a product with batch number 95JRRQFR produced by Anaiji;

[0062] Ammonium sulfate is a product with batch number P2185552 produced by Shanghai Titan Technology Co., Ltd.;

[0063] Chloroform was produced by Shanghai Lingfeng Chemical Reagent Co., Ltd. with batch number 20230421;

[0064] Sodium sulfate uses the product with batch number 20230208 produced by Jiangsu Qiangsheng Functional Chemical Co., Ltd.; sodium hydroxide uses the product with batch number 20230308 produced by Jiangsu Qiangsheng Functional Chemical Co., Ltd.;

[0065] Pyridine was produced by Shanghai Lingfeng Chemical Reagent Co., Ltd. with batch number 20230621;

[0066] Acetic anhydride was produced by Shanghai Lingfeng Chemical Reagent Co., Ltd. with batch number 20230412;

[0067] Acetic acid was produced by Shanghai Lingfeng Chemical Reagent Co., Ltd. with batch number 20230409;

[0068] Methanol was produced by Shanghai Lingfeng Chemical Reagent Co., Ltd. with batch number 20230405;

[0069] 1,4-Dioxane used was a product with batch number 20230508 produced by Shanghai Lingfeng Chemical Reagent Co., Ltd. Example 1

[0070] Synthesis of compound 2

[0071] 1) Add 46.44 g of HMDS (hexamethyldisilazane) into the reactor R1 under nitrogen protection;

[0072] 2) Add 12.0 g of cytosine into the reactor R1 under nitrogen protection;

[0073] 3) Adjust the temperature of the reactor to 135°C and continue stirring the reaction for 3 hours;

[0074] 4) The reaction is complete during HPLC control;

[0075] 5) The reaction liquid in R1 is evaporated to dryness under reduced pressure using an oil pump to obtain intermediate 1;

[0076] 6) Add 226.4 g CHCl3, 0.12 g ammonium sulfate and 30.0 g compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate) to R1;

[0077] 7) Adjust the temperature to 80°C;

[0078] 8) Continue stirring for 15 hours;

[0079] 9)HPLC central control;

[0080] 10) Adjust the temperature of reactor R1 to 20-25°C;

[0081] 11) Add 72 g of water to wash the organic phase;

[0082] 12) Add anhydrous sodium sulfate, dry, and filter;

[0083] 13) The residue was concentrated under reduced pressure to obtain 27 g of white solid compound 2 with a yield of 78.8%. Example 2

[0084] Synthesis of compound 3

[0085] 1) Under nitrogen protection, cool 100 mL of dry pyridine solution containing 27 g of compound 2 to 0-5 °C;

[0086] 2) Add 7.3 g of acetic anhydride dropwise;

[0087] 3) Stir overnight at room temperature;

[0088] 4) HPLC central control;

[0089] 5) Add 5 mL of methanol to quench the reaction;

[0090] 6) Concentration under reduced pressure;

[0091] 7) The crude product was purified by column chromatography (silica gel 200-300 mesh, column 8*50 cm, eluent: dichloromethane / methanol = 50 / 1-10 / 1) to obtain 26.7 g of compound 3, with a yield of 90%. Example 3

[0092] Synthesis of compound 4

[0093] 1) Under ice bath, dissolve 25 g of compound 3 in 50 mL of 1,4-dioxane;

[0094] 2) At 0-5°C, slowly add 50.5 mL of 1 mol / L NaOH aqueous solution;

[0095] 3) HPLC detection reaction;

[0096] 4) After the reaction is completed, add a methanol solution containing 1 mol / L acetic acid at 0-5°C until the pH is 6-7;

[0097] 5) Concentrate the organic phase under reduced pressure;

[0098] 6) Column chromatography purification (silica gel 200-300 mesh, column 8*50 cm, eluent: dichloromethane / methanol = 50 / 1-20 / 1) to obtain 13.35 g of compound 4 with a yield of 92.1%.

[0099] Compound 4 is 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone, with the structure Figure 4 As shown, the NMR data are as follows:1 H NMR (400 MHz, DMSO-d6): 10.96(s, 1H), 8.18-8.20(d,1H), 7.26-7.28 (d,1H), 6.12-6.17 (dd,1H), 5.93-5.94 (d, 1H), 5.18-5.03(m,1H), 5.11-5.14 (t,1H), 4.21-4.28 (m,1H), 3.91-3.94 (q, 1H), 3.58-3.68 (m,2H), 2.13 (s,3H). H NMR spectrum: Figure 5 , HPLC purity spectrum see Figure 6 , HPLC purity greater than 97%.

[0100] Comparison example

[0101] As the compound D1 mentioned in the background technology, its synthesis route is as follows Figure 1 As shown,

[0102] The specific steps are as follows:

[0103] Step A:

[0104] 1.30min Benzoyl chloride (2.3 mL, 20 mmol) was added dropwise to cytosine (1.1 g, 10 mmol) in dry pyridine;

[0105] 2. Stir the reaction at room temperature for 4 hours;

[0106] 3. Add a small amount of methanol to quench the reaction;

[0107] 4. Filter and rinse the filter cake with ethanol;

[0108] 5. Vacuum drying to obtain 1.92 g of compound A, yield: 90%;

[0109] Step B:

[0110] 1. Add compound A (1.29 mol, 2.0 equivalents), 900 g HMDS (hexamethyldisilazane), and 69 g ammonium sulfate;

[0111] 2. React at 130-140°C and stir for 10 hours;

[0112] 3. Cool to room temperature and add 15L chloroform;

[0113] 4. Heat to 65-75℃ and stir for 16h;

[0114] 5. Cool down to 0-10℃, add 1.5L of water;

[0115] 6. After the addition is complete, heat to 20-30°C and stir for 4-10 hours;

[0116] 7. Filter and wash the mother liquor with 1.5 L of water;

[0117] 8. Concentrate the organic phase to 0.6-0.9 L, maintain the temperature at 20-30°C, and then add 3 L of n-heptane;

[0118] 9. After the addition is complete, stir for 2-3 hours;

[0119] 10. Filter and rinse the filter cake with n-heptane;

[0120] 11. Vacuum drying gave an off-white compound B with a yield of 92.3%.

[0121] Step C:

[0122] 1. Add 100 g of compound B to 1 L of 7 mol / L ammonia methanol solution (7 mol / L);

[0123] 2. The reaction was stirred at 25-35°C for 50-60h;

[0124] 3. Concentrate under reduced pressure at 40-50°C;

[0125] 4. At 40-50℃, add 100mL methanol to dissolve;

[0126] 5. After cooling to 25-35°C, add 1L of dichloromethane dropwise;

[0127] 6. After the addition is complete, cool to 0-10℃ and stir for 2-4h;

[0128] 7. Filter and wash the filter cake with dichloromethane;

[0129] 8. Vacuum drying gave an off-white compound C with a yield of 93.2%;

[0130] Step D:

[0131] 1.1 g (about 4 mmol) of compound C was dried with 20 mL*2 anhydrous pyridine and 10 mL*2 anhydrous acetonitrile;

[0132] 2. Then, add 40 mL of anhydrous DMF;

[0133] 3. Add 0.6 mL (about 4.4 mmol) of acetic anhydride;

[0134] 4. Add 0.5 mL (4.4 mmol) triethylamine dropwise for one day;

[0135] 5. Concentrate under reduced pressure;

[0136] 6. Rinse the crude product with 50 mL of ether and dry it in vacuum;

[0137] 7. Column chromatography purification (silica gel 60H, column 4*10cm, eluent: DCM containing 0.1% pyridine, gradient methanol);

[0138] 8. Obtained compound D1 0.83 g, yield 71%;

[0139] The above original process requires 4 steps of reaction, and the total yield is: 55.0%; while the present invention only requires 3 steps of reaction, and the total yield is: 65.3%, which shortens the reaction steps and improves the yield, has obvious advantages, and is conducive to later scale-up production.

[0140] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. Therefore, based on the innovative concept of the present invention, changes and modifications to the embodiments described herein, or equivalent structural or equivalent process transformations made using the contents of the specification and drawings of the present invention, directly or indirectly applying the above technical solutions to other related technical fields are all included in the protection scope of the patent of the present invention.

Claims

1. A novel method for synthesizing 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone, characterized in that: The following steps are involved: (1) The amine group on cytosine is protected with trimethylsilane by HMDS (hexamethyldisilazane) to obtain intermediate 1; under the catalytic action of ammonium sulfate, intermediate 1 reacts with compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate), and then the trimethylsilane protection is removed by hydrolysis to obtain compound 2; (2) Acetylation of the amino group of compound 2 by acetic anhydride to obtain compound 3; (3) The two benzoic acid esters were hydrolyzed by sodium hydroxide to finally obtain compound 4, i.e., 4-acetylamino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranoyl)-2(1H)-pyrimidinone; The synthetic route is shown in the following formula I: Formula I; The step (1) comprises the following steps: 1) Add 46.44 g of HMDS (hexamethyldisilazane) into the reactor R1 under nitrogen protection; 2) Add 12.0 g of cytosine into the reactor R1 under nitrogen protection; 3) Adjust the temperature of the reactor to 135°C and continue stirring the reaction for 3 hours; 4) The reaction is complete during HPLC control; 5) The reaction liquid in R1 is evaporated to dryness under reduced pressure in an oil pump to obtain intermediate 1; 6) Add 226.4 g CHCl3, 0.12 g ammonium sulfate and 30.0 g compound 1 (2-deoxy-2-fluoro-ALPHA-D-arabinofuranosyl bromide 3,5-dibenzoate) to R1; 7) Adjust the temperature to 80°C; 8) Continue stirring for 15 hours; 9)HPLC central control; 10) Adjust the temperature of reactor R1 to 20-25°C; 11) Add 72 g of water to wash the organic phase; 12) Add anhydrous sodium sulfate, dry, and filter; 13) Concentrating under reduced pressure to obtain compound 2; The step (2) comprises the following steps: 1) Under nitrogen protection, cool 100 mL of dry pyridine solution containing 27 g of compound 2 to 0-5 °C; 2) Add 7.3 g of acetic anhydride dropwise; 3) Stir overnight at room temperature; 4) HPLC central control; 5) Add 5 mL of methanol to quench the reaction; 6) Concentration under reduced pressure; 7) The crude product was purified by column chromatography to obtain compound 3; The step (3) comprises the following steps: 1) Under ice bath, dissolve 25 g of compound 3 in 50 mL of 1,4-dioxane; 2) At 0-5°C, slowly add 50.5 mL of 1 mol / L NaOH aqueous solution; 3) HPLC detection reaction; 4) After the reaction is completed, add a methanol solution containing 1 mol / L acetic acid at 0-5°C until the pH is 6-7; 5) Concentrate the organic phase under reduced pressure; 6) Purify by column chromatography to obtain compound 4.